Abstract
Over the years, many different tyrosine and serine/threonine protein kinases have been selected as candidates for drug discovery activities in oncology research, based either on their overexpression and/or dysfunction in a particular organ or tissue, or through their association in deregulated signal transduction/cell cycle pathways. This review summarises current preclinical and clinical knowledge of ATP-competitive, small molecule kinase inhibitors, and receptor or ligand-competitive antibodies of selected protein kinases in which drug discovery and development activities have advanced with some success.
MeSH terms
-
Adenosine Triphosphate / pharmacology
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antineoplastic Agents / pharmacology*
-
Benzamides
-
Cell Nucleus / drug effects
-
Cell Nucleus / enzymology
-
Cytoplasm / drug effects
-
Cytoplasm / enzymology
-
Enzyme Inhibitors / pharmacology*
-
ErbB Receptors / antagonists & inhibitors
-
Genetic Therapy
-
Humans
-
Imatinib Mesylate
-
Membrane Proteins / antagonists & inhibitors
-
Piperazines / therapeutic use
-
Protein Kinase Inhibitors*
-
Protein Kinases / genetics
-
Pyrimidines / therapeutic use
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Receptors, Growth Factor / antagonists & inhibitors
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Membrane Proteins
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Receptors, Growth Factor
-
flt3 ligand protein
-
Imatinib Mesylate
-
Adenosine Triphosphate
-
Protein Kinases
-
ErbB Receptors
-
Receptor Protein-Tyrosine Kinases
-
Receptors, Vascular Endothelial Growth Factor